THE BENEFITS OF EARLIER TREATMENT WITH PARITAPREVIR/ROTANAVIR/OMBITASVIR WITH OR WITHOUT DASABUVIR IN IRELAND

Author(s)

Baj R, Kavanagh J, O'Meara M, McKinley C
AbbVie Ltd., Dublin 24, Ireland

Presentation Documents

OBJECTIVES:   Background

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PGI37

Topic

Health Policy & Regulatory

Topic Subcategory

Health Disparities & Equity

Disease

Gastrointestinal Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×